In addition, the metronomic administration of cyclophosphamide seems able to restore immune function by increasing CD4+/CD8+ T cells and depletion of T regulatory cells that may play a role in favoring tumor progression and therapy resistance [14,15,16,33,34]. This evidence concerns the gene CD8A and neoplasm.